BR112016030018A8 - sal composto de heterocíclico substituído com halogênio, antagonista do receptor de lpa, composição farmacêutica e uso do referido sal - Google Patents
sal composto de heterocíclico substituído com halogênio, antagonista do receptor de lpa, composição farmacêutica e uso do referido salInfo
- Publication number
- BR112016030018A8 BR112016030018A8 BR112016030018A BR112016030018A BR112016030018A8 BR 112016030018 A8 BR112016030018 A8 BR 112016030018A8 BR 112016030018 A BR112016030018 A BR 112016030018A BR 112016030018 A BR112016030018 A BR 112016030018A BR 112016030018 A8 BR112016030018 A8 BR 112016030018A8
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- lpa receptor
- pharmaceutical composition
- receptor antagonist
- substituted heterocyclic
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 4
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title abstract 2
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title abstract 2
- 229910052736 halogen Inorganic materials 0.000 title abstract 2
- 125000005843 halogen group Chemical group 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 2
- 150000001340 alkali metals Chemical class 0.000 abstract 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 2
- 150000001342 alkaline earth metals Chemical class 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229930192474 thiophene Natural products 0.000 abstract 1
- 150000003577 thiophenes Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SAL COMPOSTO DE HETEROCÍCLICO SUBSTITUÍDO COM HALOGÊNIO. É fornecido um novo sal composto de tiofeno substituído com a-halogênio que tem uma potente ação antagonista do receptor de LPA e é útil como um produto farmacêutico. Um sal representado pela fórmula geral (I): em que R é um átomo de hidrogênio ou um grupo metóxi; X é um átomo de halogênio; A é selecionado do grupo que consiste nos seguintes grupos: A; M é um metal alcalino ou um metal alcalinoterroso e n é 1 quando M é um metal alcalino e é 2 quando M é um metal alcalino-terroso].
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014132413 | 2014-06-27 | ||
JP2014-132413 | 2014-06-27 | ||
PCT/JP2015/068575 WO2015199234A1 (ja) | 2014-06-27 | 2015-06-26 | ハロゲン置換へテロ環化合物の塩 |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112016030018A2 BR112016030018A2 (pt) | 2017-08-22 |
BR112016030018A8 true BR112016030018A8 (pt) | 2023-05-09 |
BR112016030018B1 BR112016030018B1 (pt) | 2023-07-04 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
JPWO2015199234A1 (ja) | 2017-04-27 |
CN106458964A (zh) | 2017-02-22 |
KR20170016988A (ko) | 2017-02-14 |
MX2016017371A (es) | 2017-05-01 |
EP3162801A4 (en) | 2018-01-24 |
AU2015281021A1 (en) | 2017-01-19 |
KR102433588B1 (ko) | 2022-08-19 |
RU2017102513A (ru) | 2018-07-27 |
RU2017102513A3 (pt) | 2018-12-11 |
EP3162801A1 (en) | 2017-05-03 |
BR112016030018A2 (pt) | 2017-08-22 |
MX370408B (es) | 2019-12-11 |
US10023554B2 (en) | 2018-07-17 |
CA2953472C (en) | 2022-08-02 |
RU2689315C2 (ru) | 2019-05-27 |
AU2015281021B2 (en) | 2019-03-14 |
EP3162801B1 (en) | 2020-07-22 |
US20170158663A1 (en) | 2017-06-08 |
ES2824801T3 (es) | 2021-05-13 |
AU2015281021B9 (en) | 2019-03-28 |
CN106458964B (zh) | 2019-11-22 |
WO2015199234A1 (ja) | 2015-12-30 |
CA2953472A1 (en) | 2015-12-30 |
JP6579103B2 (ja) | 2019-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
TN2018000262A1 (en) | Substituted piperidine compound and use there of. | |
SV2018005723A (es) | Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos | |
PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
TN2018000424A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
PH12016501007A1 (en) | Substituted benzamides and methods of use thereof | |
CR20180563A (es) | Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen | |
MX2015010775A (es) | Benzoxazoles sustituidos y metodos para usarlos. | |
MX2016011992A (es) | Derivados de piperidina-diona. | |
UY34833A (es) | Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano RORy | |
MX2015011436A (es) | Triazolopiridinas sustituidas y metodos para usarlas. | |
BR112017006240A2 (pt) | novos compostos | |
MX2016017371A (es) | Sal de compuesto heterociclico sustituido con halogeno. | |
RS54730B1 (sr) | Inhibitori beta sekretaze | |
AR112787A2 (es) | Compuestos 1,5-difenil-penta-1,4-dien-3-ona | |
BR112016001979A2 (pt) | composto de tetrazolinona e uso do mesmo | |
BR112017008176A2 (pt) | método de preparação do carbonato de ácido glicérico. | |
BR112016027691A2 (pt) | Composto de tetra-hidropiridopirimidina e seus usos | |
CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
CY1125355T1 (el) | Πεντακυκλικη ενωση | |
AR103317A1 (es) | Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina | |
PH12016501343B1 (en) | Emulsion composition for skin | |
BR112015028871A2 (pt) | novos compostos de 3,4-dihidro-2h-isoquinolina-1-ona e 2,3-dihidro-isoindol-1-ona | |
AR111665A1 (es) | Derivados de 3-metil-pirrolidina-2,5-diona útiles como antagonistas del receptor cgrp | |
CU20200035A7 (es) | Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: UBE CORPORATION (JP) |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2015, OBSERVADAS AS CONDICOES LEGAIS |